2808361-18-2
Chemical Structure
Lepodisiran
Synonym(s): LY3819469
- CAS No.: 2808361-18-2
- Formula:N/A
- Molecular Weight:20720.00
SMILES: [Lepodisiran]
Biological Activity: Lepodisiran (LY3819469) is a GalNAc-conjugated, injectable small interfering RNA lipid-lowering agent characterized by rapid hepatic uptake and long-lasting effects. Lepodisiran targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran can be used in research related to atherosclerotic cardiovascular disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lepodisiran | 91.95% | Lepodisiran (LY3819469) is a GalNAc-conjugated, injectable small interfering RNA lipid-lowering agent characterized by rapid hepatic uptake and long-lasting effects. Lepodisiran targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran can be used in research related to atherosclerotic cardiovascular disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Nissen S E, et al. Lepodisiran—a long-duration small interfering RNA targeting lipoprotein (a)[J]. New England Journal of Medicine, 2025, 392(17): 1673-1683.
- [2]. Fernando P M S, et al. Lepodisiran, an siRNA targeting lipoprotein (a) for the potential future treatment of cardiovascular disease[J]. Expert Opinion on Investigational Drugs, 2024, 33(7): 657-659.
- [3]. Faisal A, et al. Lepodisiran: From genetic targeting to cardiovascular promise: A detailed narrative review of the literature. World journal of cardiology. 2025 Aug 26;17(8):109657. [Content Brief]
Keywords
